001010192 001__ 1010192
001010192 005__ 20230929112543.0
001010192 0247_ $$2doi$$a10.3988/jcn.2022.0302
001010192 0247_ $$2ISSN$$a1738-6586
001010192 0247_ $$2ISSN$$a2005-5013
001010192 0247_ $$2datacite_doi$$a10.34734/FZJ-2023-03003
001010192 0247_ $$2pmid$$a37417432
001010192 0247_ $$2WOS$$aWOS:001026974600005
001010192 037__ $$aFZJ-2023-03003
001010192 082__ $$a610
001010192 1001_ $$0P:(DE-HGF)0$$aBurghaus, Lothar$$b0$$eCorresponding author
001010192 245__ $$aPrehospital Levetiracetam Use in Adults With Status Epilepticus: Results of a Multicenter Registry
001010192 260__ $$aSeoul$$b[Verlag nicht ermittelbar]$$c2023
001010192 3367_ $$2DRIVER$$aarticle
001010192 3367_ $$2DataCite$$aOutput Types/Journal article
001010192 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1692187729_26395
001010192 3367_ $$2BibTeX$$aARTICLE
001010192 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001010192 3367_ $$00$$2EndNote$$aJournal Article
001010192 520__ $$aBackground and PurposeStatus epilepticus (SE) is a neurological emergency due to prolonged seizure activity or multiple seizures without full recovery in between them. Prehospital SE management is crucial since its duration is correlated with higher morbidity and mortality rates. We examined the impact of different therapeutic strategies in the prehospital setting with a focus on levetiracetam.MethodsWe initiated the Project for SE in Cologne, a scientific association of all neurological departments of Cologne, the fourth-largest city in Germany with around 1,000,000 inhabitants. All patients with an SE diagnosis were evaluated over 2 years (from March 2019 to February 2021) to determine whether prehospital levetiracetam use had a significant effect on SE parameters.ResultsWe identified 145 patients who received initial drug therapy in the prehospital setting by professional medical staff. Various benzodiazepine (BZD) derivatives were used as first-line treatments, which were mostly used in line with the recommended guidelines. Levetiracetam was regularly used (n=42) and mostly in combination with BZDs, but no significant additional effect was observed for intravenous levetiracetam. However, it appeared that the administered doses tended to be low.ConclusionsLevetiracetam can be applied to adults with SE in prehospital settings with little effort. Nevertheless, the prehospital treatment regimen described here for the first time did not significantly improve the preclinical cessation rate of SE. Future therapy concepts should be based on this, and the effects of higher doses should in particular be reexamined.	Keywords:neurological emergency; prehospital setting; anticonvulsant therapy; benzodiazepines; levetiracetam
001010192 536__ $$0G:(DE-HGF)POF4-5251$$a5251 - Multilevel Brain Organization and Variability (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001010192 536__ $$0G:(GEPRIS)491111487$$aDFG project 491111487 - Open-Access-Publikationskosten / 2022 - 2024 / Forschungszentrum Jülich (OAPKFZJ) (491111487)$$c491111487$$x1
001010192 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001010192 7001_ $$00000-0002-6299-8238$$aMadlener, Marie$$b1
001010192 7001_ $$00000-0002-4429-0367$$aKohle, Felix$$b2
001010192 7001_ $$aBruno, Emanuel F.$$b3
001010192 7001_ $$00000-0003-1607-2116$$aLimmroth, Volker$$b4
001010192 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon Rudolf$$b5$$ufzj
001010192 7001_ $$00000-0003-2535-4553$$aMalter, Michael P.$$b6
001010192 773__ $$0PERI:(DE-600)2500489-X$$a10.3988/jcn.2022.0302$$gVol. 19, no. 4, p. 365 -$$n4$$p365 -$$tJournal of clinical neurology$$v19$$x1738-6586$$y2023
001010192 8564_ $$uhttps://juser.fz-juelich.de/record/1010192/files/PDF.pdf$$yOpenAccess
001010192 909CO $$ooai:juser.fz-juelich.de:1010192$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
001010192 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b5$$kFZJ
001010192 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5251$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001010192 9141_ $$y2023
001010192 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-03-30
001010192 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
001010192 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-05-12T12:46:13Z
001010192 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-05-12T12:46:13Z
001010192 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-03-30
001010192 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001010192 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
001010192 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
001010192 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
001010192 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Double anonymous peer review$$d2022-05-12T12:46:13Z
001010192 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
001010192 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
001010192 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN NEUROL : 2022$$d2023-08-24
001010192 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-24
001010192 920__ $$lyes
001010192 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001010192 980__ $$ajournal
001010192 980__ $$aVDB
001010192 980__ $$aUNRESTRICTED
001010192 980__ $$aI:(DE-Juel1)INM-3-20090406
001010192 9801_ $$aFullTexts